

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MedSci Healthcare Holdings Limited

梅斯健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2415)

INSIDE INFORMATION PROFIT WARNING

This announcement is made by MedSci Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on its preliminary assessment of the Group’s unaudited consolidated management accounts for the six months ended 30 June 2024 (the “**Reporting Period**”) and information currently available to the Board, it is expected that the net profit for the Reporting Period would be decreased to not more than RMB500,000 as compared with that of RMB11.9 million for the six months ended 30 June 2023 (the “**Corresponding Period**”) primarily due to (i) a decrease in revenue of the Group during the Reporting Period as compared to that of the Corresponding Period arising from a temporary delay in revenue recognition of projects in precision omni-channel marketing solutions and real-world clinical study solutions due to postponement in execution of projects; (ii) the absence of fair value gains on convertible redeemable preferred shares which amounted to approximately RMB12.8 million for the Corresponding Period; and (iii) the increase in administrative expenses caused by the grant of share awards pursuant to the share award scheme of the Company. Notwithstanding the above, the Company is expected to remain profitable, and the gross profit margin for the Reporting Period is expected to be higher than that of the Corresponding Period. The Company is confident in its strategic direction and remains committed to optimising its operations and driving long-term value for the Shareholders.

As the results for the Reporting Period have not been finalized, the information contained in this announcement is only a preliminary assessment by the Board based on information currently available including the unaudited consolidated management accounts of the Group for the Reporting Period, which have not been confirmed, reviewed or audited by the auditor of the Company. Such financial information will be subject to finalisation and necessary adjustments. The details of the interim results of the Group for the Reporting Period will be disclosed in the interim results announcement of the Company, which is expected to be published by the end of August 2024.

Shareholders and potential investors should exercise caution when dealing in the shares of the Company.

By order of the Board
MedSci Healthcare Holdings Limited
梅斯健康控股有限公司
Dr. Zhang Fabao

Chairman of the Board and Executive Director

Hong Kong, 26 August 2024

As at the date of this announcement, the Board of Directors comprises Dr. Zhang Fabao, Dr. Li Xinmei, Mr. Fan Jie and Mr. Wang Shuai, as executive Directors; Mr. Hu Xubo and Mr. Yan Shengfeng, as non-executive Directors; and Ms. Liu Tao, Mr. Yu Mingyang and Mr. Lau Yiu Kwan Stanley, as independent non-executive Directors.